Novartis has announced plans to move its UK headquarters to an ‘emerging life sciences cluster’ in West London, 50 minutes’ drive from its current location in Surrey.
PRA Health Sciences has launched a new site network focused on improving pediatric clinical development and access to novel medicines in this special patient population.
Evotec and Immuneering are combining iPSC and AI technologies through a research collaboration to discover novel small molecules for rare hereditary metabolic diseases.
GW Pharma has told investors its capacity is “more than sufficient” to meet launch requirements in Europe next year, where the firm’s CBD medicine Epidiolex is under review.
The new recommendations look to provide a more efficient and effective means of qualifying clinical trial investigators – to help teams ‘conduct better, more efficient clinical trials,’ says CTTI exec.
Cyclica, a Bayer G4A company, will work with Bayer to advance drug discovery. The collaboration will involve looking further into polypharmacological profiles of small molecules.
The industry must be “relentless” in driving the adoption of new advances in technology, says Janssen, which has shifted from doing things for patients and investigators, to doing things with them.
WHO recently assessed Biopharma Services, which demonstrated compliance across multiple regulatory and organizational guidelines – opening the doors to conduct more work with the WHO foundations.
Fusion Antibodies signed an agreement with Analytics Engines to bring machine learning and AI to its humanization platform in an aim to bolster product quality and manufacturability.
QPS has expanded its Phase I clinical trial capabilities by more than 20% and doubled its lab space, which will allow the CRO to accommodate ‘exponentially more sponsors’ as demand continues to increase.
The Indian firm is relocating manufacturing operations in New Jersey, from its Cranbury facility to New Brunswick, in an effort to “improve cost efficiencies” across the US.
Pharma companies have improved or maintained standards for effective drug recalls, product packaging and managing supply in LMICs, according to the report.
World Courier has made a multimillion-dollar investment in its supply chain technology to help meet the expanding needs of the pharmaceutical industry.
Rather than limit health care data collection, the industry should focus on ensuring those data sets are used ‘in the most appropriate way,’ according to Health iQ chief commercial officer.
Takeda’s aim to acquire Shire for $62bn received a boost after regulators vote positively to approve the transaction following the divestment of Shire’s IBD drug.
Moving forward, China will take a more integral role in global drug development, following several regulatory changes designed to accelerate innovation.
Blockchain provides real-time visibility into the entire clinical trial supply chain and has the potential to solve several of the industry’s biggest challenges.
As sponsors drive CROs to consolidate, building a firm the size of Iqvia would take more than 20 years organically, says consultant – who shares the stuff of nightmares (and dreams).
Quanterix is expanding its biomarker technology platform to oncology with the launch of a new test bed for up to 10-plex assays, which will enable drug developers to expedite clinical trials, says CEO.
The PE firm Ampersand Capital Partners has acquired Pacific Biomarkers and is merging the CRO with Neomed-Labs to streamline clinical immunology development.
Dr. Reddy’s Laboratories site in Visakhapatnam, India, was issued a Form 483 last month, yet shares rose after a more recent audit where zero observations were noted.
Iqvia describes the new platform as the marriage of eConsent with an authoring system – giving the clinical trial a framework for transparency and transformational change.
The predictive value of animal models is less than 50%, which makes them less informative than a coin flip, says AAPS speaker – who also argues that clinical trial participants are not fully aware of the risks.
More than six million pet dogs are diagnosed with cancer every year – posing researchers with the opportunity to co-develop drugs for humans and animals.
The FDA has proposed a study to create a non-animal based model for drug development as part of its overall commitment to reduce the number of animals used in research.
Strong collaboration across the company’s clinical, commercial, and integration solutions teams led to a “solid performance,” said Syneos CEO Alistair MacDonald.
Synteract’s clients will benefit from a single source model, says CEO, following the acquisition of KinderPharm, a PA-based CRO focused on all phases of pediatric drug development.
